Could the COVID-19-Driven Increased Use of Ivermectin Lead to Incidents of Imbalanced Gut Microbiota and Dysbiosis?
Probiotics Antimicrob Proteins
; 14(2): 217-223, 2022 04.
Article
in English
| MEDLINE | ID: covidwho-1712365
ABSTRACT
The microfilaricidal anthelmintic drug ivermectin (IVM) has been used since 1988 for treatment of parasitic infections in animals and humans. The discovery of IVM's ability to inactivate the eukaryotic importin α/ß1 heterodimer (IMPα/ß1), used by some viruses to enter the nucleus of susceptible hosts, led to the suggestion of using the drug to combat SARS-CoV-2 infection. Since IVM has antibacterial properties, prolonged use may affect commensal gut microbiota. In this review, we investigate the antimicrobial properties of IVM, possible mode of activity, and the concern that treatment of individuals diagnosed with COVID-19 may lead to dysbiosis.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Gastrointestinal Microbiome
/
COVID-19 Drug Treatment
Limits:
Animals
Language:
English
Journal:
Probiotics Antimicrob Proteins
Year:
2022
Document Type:
Article
Affiliation country:
S12602-022-09925-5
Similar
MEDLINE
...
LILACS
LIS